Kyntra Bio (KYNB) Common Equity (2016 - 2025)
Historic Common Equity for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$17.0 million.
- Kyntra Bio's Common Equity rose 9301.18% to -$17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.0 million, marking a year-over-year increase of 9301.18%. This contributed to the annual value of -$225.6 million for FY2024, which is 1049.93% down from last year.
- Kyntra Bio's Common Equity amounted to -$17.0 million in Q3 2025, which was up 9301.18% from -$223.0 million recorded in Q2 2025.
- In the past 5 years, Kyntra Bio's Common Equity registered a high of $390.3 million during Q1 2021, and its lowest value of -$243.7 million during Q3 2024.
- In the last 5 years, Kyntra Bio's Common Equity had a median value of -$48.9 million in 2023 and averaged -$17.3 million.
- Its Common Equity has fluctuated over the past 5 years, first tumbled by 85195.6% in 2023, then surged by 9301.18% in 2025.
- Over the past 5 years, Kyntra Bio's Common Equity (Quarter) stood at $229.1 million in 2021, then plummeted by 109.36% to -$21.4 million in 2022, then crashed by 851.96% to -$204.2 million in 2023, then decreased by 10.5% to -$225.6 million in 2024, then skyrocketed by 92.45% to -$17.0 million in 2025.
- Its Common Equity was -$17.0 million in Q3 2025, compared to -$223.0 million in Q2 2025 and -$216.9 million in Q1 2025.